---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031088"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:24:10.056633+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Oncocyte amends bylaws to allow President role independent of CEO

## Summary
- Board approved Second Amended and Restated Bylaws effective November 3, 2022.
- Amendment permits appointment of a President without requiring the CEO to also serve as President.
- Full text of amended bylaws is filed as Exhibit 3.1 to the Form 8-K.

## SEC filing metadata
- accession: 0001493152-22-031088
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031088/0001493152-22-031088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031088/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031088
- JSON: https://secwatch.observer/filing/0001493152-22-031088.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031088.txt

## Key facts
- Governance Changes
  Insight Molecular Diagnostics Inc.: Adopted Second Amended and Restated Bylaws on November 3, 2022, allowing the Company to appoint a President or Presidents without requiring the CEO to also be a President (effective 2022-11-03).
  - Change: bylaw amendment
  - Effective: 2022-11-03
  source text: On and effective as of November 3, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “Bylaws”), pursuant to which the Company may appoint a President or Presidents without requiring that the chief executive officer also be a President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031088/0001493152-22-031088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.